Search Within
V-016
Applied Filters:
Keyword:'V-016'
Showing 1-30 of 190 results for "V-016" within Papers
Farhad Ravandi et al.
Blood, 121(23), 4655-4662 (2013-04-25)
Patients received 5-azacytidine (AZA) 75 mg/m(2) intravenously daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ~1-month intervals. Forty-three acute myeloid leukemia (AML) patients with a median age of 64 years (range, 24-87
M V Gammons et al.
British journal of cancer, 111(3), 477-485 (2014-07-11)
Current therapies for metastatic melanoma are targeted either at cancer mutations driving growth (e.g., vemurafenib) or immune-based therapies (e.g., ipilimumab). Tumour progression also requires angiogenesis, which is regulated by VEGF-A, itself alternatively spliced to form two families of isoforms, pro-
Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis.
Xia Jiang et al.
Experimental cell research, 323(2), 326-336 (2014-03-04)
Previous studies demonstrated that androgen receptor (AR) is expressed in human hepatocellular carcinoma (HCC), one of the male-dominant diseases. Glucose-regulated protein 78 kDa (GRP78/Bip), which has a role in cancer development, is one of the androgen response genes in prostate
Topical niacinamide and barrier enhancement.
Donald Bissett
Cutis, 70(6 Suppl), 8-12 (2002-12-25)
Yuichi Honma et al.
Journal of UOEH, 36(4), 229-235 (2014-12-17)
The prognosis of advanced hepatocellular carcinoma (HCC) has remained very poor.It has recently been reported that the molecular targeting agent sorafenib can improve the prognosis of patients with advanced HCC. However, the detailed mechanisms of sorafenib, especially its direct effects
Qi-Han Fu et al.
Journal of cancer research and clinical oncology, 140(8), 1429-1440 (2014-04-29)
Combination therapy of sorafenib and transarterial chemoembolization (TACE) showed benefits for hepatocellular carcinoma (HCC). This systematic review aims for evaluation of efficacy and safety between sorafenib plus TACE and TACE alone for HCC. We systematically searched multi-databases to identify eligible
Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.
Juliet Fraser Gibson et al.
British journal of haematology, 167(1), 141-144 (2014-06-04)
Nayeli Torres-Ramírez et al.
Life sciences, 93(25-26), 975-985 (2013-11-05)
Excessive energy uptake of dietary carbohydrates results in their storage as fat and requires glucose-6-phosphate dehydrogenase (G6PD)-mediated NADPH production. We sought to assess whether the nicotinamide-induced reduction of G6PD activity might modulate redox balance and lipid accumulation in 3T3-L1 cells.
Sirtuins: Longevity focuses on NAD+.
Heinrich Jasper
Nature chemical biology, 9(11), 666-667 (2013-10-22)
A rare primary liver tumor that responded to sorafenib.
Satoshi Seino et al.
Gastroenterology, 147(6), 1226-1227 (2014-12-03)
Manisha Sonee et al.
Neurotoxicity research, 4(7-8), 595-599 (2003-04-24)
In previous studies with mice the oxygen radical generating neurotoxin tertiary butylhydroperoxide (t-BuOOH) was used to mimic the oxidative injury that has been implicated in neurodegenerative diseases. In addition, previous studies have shown that the poly (ADP-ribose) polymerase (PARP) inhibitor
Inge M Westra et al.
Toxicology and applied pharmacology, 274(2), 328-338 (2013-12-11)
Induction of fibrosis during prolonged culture of precision-cut liver slices (PCLS) was reported. In this study, the use of rat PCLS was investigated to further characterize the mechanism of early onset of fibrosis in this model and the effects of
Joan Fernando et al.
International journal of cancer, 136(4), E161-E172 (2014-07-24)
The multikinase inhibitor sorafenib is the only effective drug in advanced cases of hepatocellular carcinoma (HCC). However, response differs among patients and effectiveness only implies a delay. We have recently described that sorafenib sensitizes HCC cells to apoptosis. In this
Angel E Alsina et al.
The American surgeon, 80(7), 680-684 (2014-07-06)
Recurrence of hepatocellular carcinoma (HCC) remains a main detriment to long-term survival in liver transplants (LTx) for HCC. The study aims to review the use of sorafenib in recurrent HCC LTx in the Model End Stage Liver Disease era. Two
Arun Sreekumar et al.
Nature, 457(7231), 910-914 (2009-02-13)
Multiple, complex molecular events characterize cancer development and progression. Deciphering the molecular networks that distinguish organ-confined disease from metastatic disease may lead to the identification of critical biomarkers for cancer invasion and disease aggressiveness. Although gene and protein expression have
Tomasz Szkudelski
Experimental biology and medicine (Maywood, N.J.), 237(5), 481-490 (2012-05-24)
Administration of both streptozotocin (STZ) and nicotinamide (NA) has been proposed to induce experimental diabetes in the rat. STZ is well known to cause pancreatic B-cell damage, whereas NA is administered to rats to partially protect insulin-secreting cells against STZ.
Małgorzata Natalia Mojsak et al.
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 29(169), 54-57 (2010-08-18)
Nicotinamide (niacin) is very useful substance in treatment of many kinds of diseases. For the decades the main indications for application of niacin were lipid disorders. There are studies confirming that niacin increases thyroid radiosensitivity to 1-131. The radioiodine therapy
Amanda Rennick et al.
Pharmacotherapy, 33(6), 683-690 (2013-03-26)
Phosphate binders have traditionally been used to treat hyperphosphatemia, a common complication in patients with end stage renal disease (ESRD). New evidence suggests that nicotinic acid and its metabolites may effectively decrease phosphorus absorption in the gastrointestinal tract, thereby reducing
Shin-Ichiro Imai
Current pharmaceutical design, 15(1), 20-28 (2009-01-20)
New interest in NAD biology has recently been revived, and enzymes involved in NAD biosynthetic pathways have been identified and characterized in mammals. Among them, nicotinamide phosphoribosyltransferase (Nampt) has drawn much attention in several different fields, including NAD biology, metabolism
Utilization of niacin and niacinamide for NAD formation in rat liver.
Nutrition reviews, 30(6), 139-141 (1972-06-01)
Calin Cainap et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(2), 172-179 (2014-12-10)
This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy. Patients were randomly assigned in a 1:1 ratio to linifanib 17.5 mg once daily or sorafenib
Pamela Biondani et al.
Anticancer research, 34(5), 2395-2398 (2014-04-30)
Only scanty data are available to evaluate the impact of sequential TKIs on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). This retrospective study investigated the efficacy of the sequence sorafenib-sunitinib (SO-SU) and vice versa (SU-SO) in
Ryota Mukai et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(12), 1813-1815 (2014-01-08)
We report a case of multiple intrahepatic recurrence of hepatocellular carcinoma( HCC) that was successfully treated with transcatheter arterial chemoembolization( TACE) and sorafenib therapy. A 73-year-old man was diagnosed as having multiple intrahepatic recurrence in segment 2 (S2) and segment
Nobuaki Matsubara et al.
Urology, 82(1), 118-123 (2013-06-29)
To reveal the outcomes of initial active surveillance (AS), followed by deferred systemic target therapy, in a subpopulation of patients with indolent metastatic renal cell carcinoma (mRCC). We retrospectively reviewed the clinical and pathologic data of patients with mRCC, who
Devalingam Mahalingam et al.
Cancer chemotherapy and pharmacology, 74(1), 77-84 (2014-05-13)
Melanomas are vascular tumors with a high incidence of BRAF mutations driving tumor proliferation. Complete inhibition of vascular endothelial growth factor (VEGF) signaling has potential for enhanced antitumor efficacy. Patients with advanced melanoma and adequate organ function were eligible. Sorafenib
M Denorme et al.
Cancer letters, 352(2), 236-244 (2014-07-13)
Pheochromocytomas and paragangliomas are rare neuroendocrine tumors which develop from chromaffin cells of the adrenal medulla and extra-adrenal sites, leading to excess catecholamine release and hypertension. Many of the tumors are characterized by a high vascularity, suggesting the possible implementation
Asghar Ghasemi et al.
Acta physiologica Hungarica, 101(4), 408-420 (2014-12-24)
Diabetes is one of the five leading causes of death in the world, with type 2 diabetes occurring more frequently than type 1. Management of diabetes without side effects is still a challenge and therefore new strategies need to be
Danny J Scholten et al.
Molecular pharmacology, 85(1), 116-126 (2013-11-01)
CXC chemokine receptor CXCR3 and/or its main three ligands CXCL9, CXCL10, and CXCL11 are highly upregulated in a variety of diseases. As such, considerable efforts have been made to develop small-molecule receptor CXCR3 antagonists, yielding distinct chemical classes of antagonists
New era for treatment in differentiated thyroid cancer.
Sigurdis Haraldsdottir et al.
Lancet (London, England), 384(9940), 286-288 (2014-04-29)
Pancreatic atrophy--a new late toxic effect of sorafenib.
Ségolène Hescot et al.
The New England journal of medicine, 369(15), 1475-1476 (2013-10-11)
Page 1 of 7